world
FDA Issues Priority Vouchers to Three Companies for Psychedelic Medication Reviews
The Food and Drug Administration announced on April 24, 2026, that it is issuing national priority vouchers to three companies to fast-track reviews of psychedelic medications. The companies are studying psilocybin for depression and methylone for PTSD. The move follows President Trump's executive order to expedite such research.
AB
propublica.orgAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The Food and Drug Administration announced on April 24, 2026, that it is issuing national priority vouchers to three companies to help fast-track the review of certain psychedelic medications. The vouchers aim to accelerate the evaluation of psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone for post-traumatic stress disorder, @ABC reported.
FDA Commissioner Dr.
' The agency also announced it is allowing an early phase clinical study of noribogaine hydrochloride to move forward following an Investigational New Drug submission. Noribogaine hydrochloride is the principal psychoactive substance of the drug ibogaine.
The announcements follow President Donald Trump's executive order, signed over the weekend prior to April 24, 2026, directing the FDA to expedite its review of certain psychedelics.
The order seeks to accelerate research and approval of psychedelic-based therapies to treat mental health conditions including PTSD, depression and addiction. Psilocybin mushrooms were photographed standing ready for harvest in a humidified fruiting chamber in the basement of a private home on July 28, 2023, in Fairfield County, Connecticut.
